{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:16:36Z","timestamp":1793448996288,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-RHUS-0012"],"award-info":[{"award-number":["ANR-18-RHUS-0012"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.neurol.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T09:30:59Z","timestamp":1678959059000},"page":"506-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-0185","authenticated-orcid":false,"given":"A.","family":"Farina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9236-2428","authenticated-orcid":false,"given":"M.","family":"Villagr\u00e1n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.neurol.2023.03.003_bib0290","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.003_bib0295","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0300","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.neurol.2023.03.003_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.003_bib0310","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2023.03.003_bib0315","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.neurol.2023.03.003_bib0320","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.003_bib0325","doi-asserted-by":"crossref","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0330","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.neurol.2023.03.003_bib0335","first-page":"S74","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.","volume":"24","author":"Psimaras","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.003_bib0340","doi-asserted-by":"crossref","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.003_bib0345","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.003_bib0350","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0355","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp-2021-326369","article-title":"Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours","volume":"93","author":"Chompoopong","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.003_bib0360","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2023.03.003_bib0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.003_bib0370","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00415-021-10870-6","article-title":"How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.","volume":"269","author":"Vogrig","year":"2022","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2023.03.003_bib0375","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0380","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.003_bib0385","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.003_bib0390","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2023.03.003_bib0395","doi-asserted-by":"crossref","first-page":"9800488","DOI":"10.1155\/2021\/9800488","article-title":"Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases","volume":"2021","author":"Li","year":"2021","journal-title":"BioMed Res Int"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.003_bib0400","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0405","doi-asserted-by":"crossref","first-page":"e200058","DOI":"10.1212\/NXI.0000000000200058","article-title":"Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors","volume":"10","author":"Farina","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.003_bib0410","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2023.03.003_bib0415","doi-asserted-by":"crossref","first-page":"538695","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.003_bib0420","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.003_bib0425","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","article-title":"Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review","volume":"97","author":"Nersesjan","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.003_bib0430","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.003_bib0435","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2023.03.003_bib0440","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2022.08.009","article-title":"Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study","volume":"175","author":"M\u00fcller-Jensen","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.003_bib0445","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.003_bib0450","doi-asserted-by":"crossref","first-page":"e001034","DOI":"10.1136\/jitc-2020-001034","article-title":"Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients","volume":"8","author":"Cuzzubbo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.neurol.2023.03.003_bib0455","unstructured":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors | Neurology Neuroimmunology & Neuroinflammation. [Accessed November 5, 2022. https:\/\/nn.neurology.org\/content\/8\/3\/e967]."},{"issue":"2","key":"10.1016\/j.neurol.2023.03.003_bib0460","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.003_bib0465","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s10072-022-05920-4","article-title":"Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice","volume":"43","author":"Villagr\u00e1n-Garc\u00eda","year":"2022","journal-title":"Neurol Sci"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.003_bib0470","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.003_bib0475","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ccr3.2122","article-title":"Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer","volume":"7","author":"Kim","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.neurol.2023.03.003_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8865054","article-title":"Diagnosis and differential diagnosis of neurological adverse events during immune checkpoint inhibitor therapy. Coppola V, ed","volume":"2020","author":"M\u00f6hn","year":"2020","journal-title":"J Oncol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.003_bib0485","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"36","key":"10.1016\/j.neurol.2023.03.003_bib0490","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.neurol.2023.03.003_bib0495","doi-asserted-by":"crossref","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0500","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.003_bib0505","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.003_bib0510","doi-asserted-by":"crossref","first-page":"fcab220","DOI":"10.1093\/braincomms\/fcab220","article-title":"Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae","volume":"3","author":"Pla\u00e7ais","year":"2021","journal-title":"Brain Commun"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0515","doi-asserted-by":"crossref","first-page":"ltac012","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0520","doi-asserted-by":"crossref","first-page":"e000842","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.003_bib0525","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-interleukin-6 and janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.003_bib0530","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor\u2013induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"24","key":"10.1016\/j.neurol.2023.03.003_bib0535","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.003_bib0540","doi-asserted-by":"crossref","first-page":"e002886","DOI":"10.1136\/jitc-2021-002886","article-title":"Effect of a multidisciplinary severe immunotherapy complications service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer","volume":"9","author":"Zubiri","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.neurol.2023.03.003_bib0545","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1093\/rheumatology\/keab249","article-title":"Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study","volume":"60","author":"Weill","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.neurol.2023.03.003_bib0550","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.003_bib0555","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-021-03053-9","article-title":"Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies","volume":"71","author":"Seki","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.003_bib0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.003_bib0565","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ene.15624","article-title":"Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review","volume":"30","author":"Dinoto","year":"2023","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.003_bib0570","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:35:53Z","timestamp":1777448153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378723008755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0035378723008755"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}